A Phase II Randomized, Placebo-Controlled Study of GBT440 to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

A Phase II Randomized, Placebo-Controlled Study of GBT440 to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs GBT 440 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Global Blood Therapeutics
  • Most Recent Events

    • 14 Sep 2016 According to a Global Blood Therapeutics media release, data from this trial are expected in the second half of 2017.
    • 05 Apr 2016 New trial record
    • 29 Mar 2016 According to a Global Blood Therapeutics media release, this trial is expected to start in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top